Aspirin’s Limits in Cancer Prevention

Daily aspirin use is not a reliable way to prevent colorectal cancer in people at average risk.
A major review finds that any potential benefit may take more than a decade to appear, while bleeding risks begin immediately.
Experts emphasize that decisions about aspirin should be individualized rather than assumed.

Weak Evidence for Long-Term Protection

A new Cochrane review concludes that daily aspirin does not reliably prevent bowel cancer in people at average risk. Researchers found that any possible protective effect may take more than ten years to emerge, and even then, the evidence supporting such a benefit is very limited. Several studies hinted at long‑term reductions in cancer risk, but those findings came from observational follow‑up periods rather than controlled trial conditions. This makes the results more vulnerable to bias, especially because participants may have changed their medication habits over time.

The review analyzed ten randomized controlled trials involving 124,837 participants to determine whether aspirin or other NSAIDs could reduce the risk of colorectal cancer or precancerous adenomas. No qualifying trials were found for non‑aspirin NSAIDs, so the conclusions apply only to aspirin. Investigators noted that aspirin likely does not reduce cancer risk within the first five to fifteen years of use. Their findings challenge the long‑held belief that aspirin offers a straightforward protective effect against colorectal cancer.

Immediate Bleeding Risks Overshadow Uncertain Benefits

The researchers found strong evidence that daily aspirin increases the risk of serious extracranial bleeding. Higher doses carry greater danger, but even low‑dose aspirin raises the likelihood of hemorrhage. Older adults and individuals with a history of ulcers or bleeding disorders face particularly elevated risks. These immediate harms contrast sharply with the uncertain and delayed potential benefits.

Experts involved in the review stressed that people should not assume aspirin provides quick or guaranteed cancer protection. Dr. Zhaolun Cai, the lead author, explained that while the idea of long‑term prevention is appealing, the evidence does not support a clear benefit for average‑risk individuals. He emphasized that the bleeding risk begins on the first day of use, making the risk‑benefit balance more complicated than many assume. Dr. Bo Zhang, a senior author, warned that misconceptions about aspirin’s preventive power could lead people to underestimate its dangers.

Not Suitable as a Universal Prevention Strategy

Earlier research has shown that aspirin may help certain high‑risk groups, such as individuals with inherited conditions like Lynch syndrome. This review, however, focused exclusively on people at average risk, and for them, the evidence supporting long‑term cancer prevention remains highly uncertain. The authors recommend that no one start aspirin for cancer prevention without consulting a healthcare professional about personal bleeding risks. Their findings reinforce the need for individualized decision‑making rather than broad public recommendations.

The researchers argue that the future of cancer prevention lies in precision approaches that consider molecular markers and personal risk profiles. Such strategies could help identify who might benefit from aspirin and who might be harmed. They also note that the balance between benefits and harms can shift over time, making ongoing evaluation essential. Dr. Dan Cao, another senior author, stated that widespread aspirin use in the general population is not supported by current evidence.

A More Complex Picture Than Once Believed

Colorectal cancer remains one of the most common cancers worldwide, and prevention efforts typically focus on lifestyle changes and routine screening. Scientists have long explored whether widely available medications like NSAIDs could offer additional protection. Aspirin’s potential role in cancer prevention has been debated for decades, but this review suggests the story is far more nuanced than earlier research implied. The authors conclude that the current evidence does not justify recommending aspirin solely for cancer prevention in average‑risk individuals.

Their analysis highlights the importance of relying on high‑quality randomized trials rather than observational data when evaluating preventive strategies. It also underscores the need for clear communication about the risks associated with common medications. Many people assume that over‑the‑counter drugs are inherently safe, yet aspirin’s bleeding risks are well documented. This review serves as a reminder that even familiar medications can carry significant harms.